These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 21353546

  • 1. Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
    Garofalo A, Goossens L, Six P, Lemoine A, Ravez S, Farce A, Depreux P.
    Bioorg Med Chem Lett; 2011 Apr 01; 21(7):2106-12. PubMed ID: 21353546
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
    Garofalo A, Farce A, Ravez S, Lemoine A, Six P, Chavatte P, Goossens L, Depreux P.
    J Med Chem; 2012 Feb 09; 55(3):1189-204. PubMed ID: 22229669
    [Abstract] [Full Text] [Related]

  • 3. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
    Garofalo A, Goossens L, Lemoine A, Farce A, Arlot Y, Depreux P.
    J Enzyme Inhib Med Chem; 2010 Apr 09; 25(2):158-71. PubMed ID: 20222760
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
    Ravez S, Barczyk A, Six P, Cagnon A, Garofalo A, Goossens L, Depreux P.
    Eur J Med Chem; 2014 May 22; 79():369-81. PubMed ID: 24747748
    [Abstract] [Full Text] [Related]

  • 5. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.
    Xi L, Zhang JQ, Liu ZC, Zhang JH, Yan JF, Jin Y, Lin J.
    Org Biomol Chem; 2013 Jul 14; 11(26):4367-78. PubMed ID: 23715382
    [Abstract] [Full Text] [Related]

  • 6. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Wissner A, Fraser HL, Ingalls CL, Dushin RG, Floyd MB, Cheung K, Nittoli T, Ravi MR, Tan X, Loganzo F.
    Bioorg Med Chem; 2007 Jun 01; 15(11):3635-48. PubMed ID: 17416531
    [Abstract] [Full Text] [Related]

  • 7. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
    Barbosa ML, Lima LM, Tesch R, Sant'Anna CM, Totzke F, Kubbutat MH, Schächtele C, Laufer SA, Barreiro EJ.
    Eur J Med Chem; 2014 Jan 01; 71():1-14. PubMed ID: 24269511
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases.
    Thompson AM, Delaney AM, Hamby JM, Schroeder MC, Spoon TA, Crean SM, Showalter HD, Denny WA.
    J Med Chem; 2005 Jul 14; 48(14):4628-53. PubMed ID: 16000000
    [Abstract] [Full Text] [Related]

  • 9. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
    Li Y, Tan C, Gao C, Zhang C, Luan X, Chen X, Liu H, Chen Y, Jiang Y.
    Bioorg Med Chem; 2011 Aug 01; 19(15):4529-35. PubMed ID: 21724404
    [Abstract] [Full Text] [Related]

  • 10. Naphthofuroquinone derivatives: inhibition of receptor tyrosine kinases.
    Lee KI, Park Y, Park SJ, Hwang JH, Lee SJ, Kim GD, Park WK, Lee S, Jeong D, Kong JY, Kang HK, Cho H.
    Bioorg Med Chem Lett; 2006 Feb 01; 16(3):737-42. PubMed ID: 16321529
    [Abstract] [Full Text] [Related]

  • 11. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
    Usui T, Ban HS, Kawada J, Hirokawa T, Nakamura H.
    Bioorg Med Chem Lett; 2008 Jan 01; 18(1):285-8. PubMed ID: 17983745
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
    Jin Y, Li HY, Lin LP, Tan J, Ding J, Luo X, Long YQ.
    Bioorg Med Chem; 2005 Oct 01; 13(19):5613-22. PubMed ID: 15993078
    [Abstract] [Full Text] [Related]

  • 13. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
    Kissau L, Stahl P, Mazitschek R, Giannis A, Waldmann H.
    J Med Chem; 2003 Jul 03; 46(14):2917-31. PubMed ID: 12825933
    [Abstract] [Full Text] [Related]

  • 14. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
    Zhang HQ, Gong FH, Li CG, Zhang C, Wang YJ, Xu YG, Sun LP.
    Eur J Med Chem; 2016 Feb 15; 109():371-9. PubMed ID: 26826581
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW, Palmer BD, Bridges AJ, Showalter HD, Sun L, Nelson J, McMichael A, Kraker AJ, Fry DW, Denny WA.
    J Med Chem; 1996 Feb 16; 39(4):918-28. PubMed ID: 8632415
    [Abstract] [Full Text] [Related]

  • 16. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity.
    Whittles CE, Pocock TM, Wedge SR, Kendrew J, Hennequin LF, Harper SJ, Bates DO.
    Microcirculation; 2002 Dec 16; 9(6):513-22. PubMed ID: 12483548
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.
    Abouzid K, Shouman S.
    Bioorg Med Chem; 2008 Aug 15; 16(16):7543-51. PubMed ID: 18678492
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
    Nakamura H, Sasaki Y, Uno M, Yoshikawa T, Asano T, Ban HS, Fukazawa H, Shibuya M, Uehara Y.
    Bioorg Med Chem Lett; 2006 Oct 01; 16(19):5127-31. PubMed ID: 16893647
    [Abstract] [Full Text] [Related]

  • 19. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.
    Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C.
    J Med Chem; 1999 Dec 30; 42(26):5369-89. PubMed ID: 10639280
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and antiproliferative properties of 4-aminoquinazoline derivatives as inhibitors of EGF receptor-associated tyrosine kinase activity.
    Bouey-Bencteux E, Loison C, Pommery N, Houssin R, Hénichart JP.
    Anticancer Drug Des; 1998 Dec 30; 13(8):893-922. PubMed ID: 10335266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.